Drug intelligence / Profile preview

T-M3

Development stage: Unknown
Lead developer: Xi'an Jiaotong-Liverpool University

Overview

T-M3: sourced facts only. name: "In this study, two mutant peptides (named T-M2 and T-M3) exhibited stronger inhibition of TIGIT-CD155 interactions than the wild-type peptide in hTIGIT-CHO-K1 cell-based blocking assay." [DOI:10.1158/1538-7445.am2026-2816]; target: "In this study, two mutant peptides (named T-M2 and T-M3) exhibited stronger inhibition of TIGIT-CD155 interactions than the wild-type peptide in hTIGIT-CHO-K1 cell-based blocking assay." [DOI:10.1158/1538-7445.am2026-2816]; developer: "Xi'an Jiaotong-Liverpool University, Suzhou, China." [DOI:10.1158/1538-7445.am2026-2816]

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on T-M3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-M3.